Param Shah, Co-Founder and CEO of FactoryFour.

FactoryFour is reinventing manufacturing management around a modern technology stack. We are replacing legacy software and spreadsheets with a real-time system of record that is highly customizable, simple to use, and quick to deploy.

Luke Cooper is CEO and Founder at Fixt. With a deep understanding of the insurance and financial services ecosystem, he oversees the company’s leadership position as the central connector of repair solutions across the ecosystem. Prior to Fixt, Luke was a founding team member of CTS, Inc. (acquired by Paradigm Holding Solutions and CACI International Inc. for $60M), a leader in cybersecurity information assurance systems.

Dr. Rapoport is a board-certified hematologist and stem cell transplant (SCT) physician, and a trailblazer in the field of regenerative medicine and immunotherapy.
He was among the first to show that combination immunotherapy with vaccine-primed and ex-vivo costimulated autologous T-cells could induce robust vaccine-specific immune responses. He also demonstrated for the first time that early adoptive transfers of costimulated T cells could induce robust T-cell recovery post-transplant in the autologous transplant setting. Most recently he has helped to pioneer the use of genetically engineered T cells to treat multiple myeloma. He has directed six major clinical trials of adoptive T-cells to treat multiple myeloma.
Dr. Rapoport received his bachelor’s degree in biology from Massachusetts Institute of Technology, and his M.D. from Harvard Medical School.

Alicia Moran is the manager of Small Business Development and “Innovation Station” for the Prince George’s County Economic Development Corporation. She brings to the table a wealth of industry, academic, finance, startup and government expertise.

Jennifer brings her passion for entrepreneurship and a strong background in the start-up community to her position at TEDCO. She joined TEDCO in 2012 as the Program Manager responsible for launching the Maryland Innovation Initiative (MII). As TEDCO’s Vice President of Business Development, Jennifer manages the development of guidelines and policies, the application and review process, marketing and outreach, and board member engagement.

Prior to joining TEDCO, Jennifer was Director of the Innovation Transfer Network (ITN), a first-of-its-kind Pennsylvania network of thirteen small colleges and universities focused on commercialization. More than $3 million dollars was awarded to ITN as a result of her leadership, in addition to national media recognition, and expansion of the program model. She also worked with multiple venture capital firms and angel investors to identify and evaluate start up opportunities for investment.

Bill founded and was president of FiberGate, Inc., a Washington D.C. metro area provider of Dark Fiber services. FiberGate developed local fiber optic backbones along strategic routes in Maryland, Washington, D.C., and Northern Virginia. Bill ran the company for 17 years and successfully exited in the fall of 2012. Currently, he invests and works with startup companies, many of which come through the Dingman Center Angels investor network. Some of Bill’s investments include Divvy Cloud, Cobrain, Vitus Vet, ZeroFox, and Pendo.io. Bill is chairman of the Dingman Center Board of Advisors.

Frank Glover is the Lead Director of TEDCO’s Seed Fund and is a member of Maryland Venture Fund’s investment team. Prior to joining TEDCO, Frank was at Greenspring Associates, a global venture investment firm, where he was responsible for investments in growth-stage companies, early-stage funds, and secondaries.
Before Greenspring, Frank held a strategic operating role at Yum! Brands. At Yum!, Frank focused on revitalization initiatives for the KFC franchise system, drawing from his experience building a franchise lending business for TD. Prior to Yum! and TD, Frank founded Odin Ventures, a pre-seed studio. Earlier in his career, Frank worked in investment banking at Barclays Capital and Piper Jaffray.

Frank holds an International MBA from University of South Carolina’s Moore School of Business and a BS in Business Administration from University of North Carolina’s Kenan-Flagler Business School. He is also a CFA charterholder and certified Project Management Professional (PMP).

John Gustin is the Award Manager for the Maryland Innovation Initiative(MII). The MII is a $5.8 million program investing in commercialization and start-up companies spinning out of five participating universities; Johns Hopkins University, the University of Maryland College Park, Baltimore and Baltimore County campuses, as well as Morgan State University. As award manager, he helps guide MII awardees to successful completion of their projects and identifies/coordinates areas of support needed to further commercialize these university technologies.

Elise Blaese is a Senior Project Manager for IBM Research. She supports the work of the research Healthcare and Life sciences team. She is currently working with scientist’s the Computational Biology Center, the The Center for Advanced Technology Solutions in Biomedicine (CATSBio) and Translational Systems Biology and Nanobiotechnology Group to manage projects including the DREAM Challenges, NanoDLD (Lab on a Chip), Nano biotechnology, and partnerships with academic medical centers.

Elise joined IBM Research in 2008 where she has been in charge of forging relationships at the NIH and NSF and finding opportunities for applying new technologies being developed in IBM Research to opportunities in these agencies particularly in the healthcare and life sciences arena. Before to joining IBM Research Elise has had a varied career in IBM’s Healthcare and Life Sciences organization working in both the Information Based Medicine and Life Sciences EBOs

Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. He also held various executive positions with Life Technologies, Inc. that included leading its global businesses, mergers and acquisitions and its initial public offering (IPO). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committees of the Alliance for Regenerative Medicine and the Biotechnology Innovation Organization. Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.

Neil Davis serves as TEDCO’s Director of Entrepreneurial Development. In this role, he manages major elements of TEDCO’s Gateway Services Initiative – the mdPACE Program, the Gateway Services Program, and the Rural Business Innovation Initiative. Neil is also the Organization’s liaison with the State’s technology incubators, is part of the TEDCO’s seed investment team, and is actively involved in creating new strategies designed to assist entrepreneurs, including the development of educational programming for TEDCO’s portfolio companies. He brings more than 30 years of experience in engineering, business development, business consulting, and P&L management.

Eric Victory is Vice President & Head for cardiovascular, renal, metabolic, and infectious diseases within the Partnering & Strategy group at MedImmune, the biologics R&D unit of AstraZeneca. He is responsible for the company’s pre-proof of concept externalization activities in CV/Renal/Metabolism & Microbial Sciences. Eric has successfully closed the acquisitions of Spirogen and Amplimmune, brought on Sanofi Pasteur as a partner, and led key agreements with Inovio Pharmaceuticals, Omnis Pharmaceuticals, the Danish Diabetes Academy, the Joslin Diabetes Center, Shionogi, Advaxis, Immunocore, ADC Therapeutics, and NGM Biopharmaceuticals.

After being diagnosed with a cervical tumor that was linked to popular feminine care products, Arion Long started Femly, a hi-tech social enterprise that manufactures and delivers safer alternatives directly to your door! Femly is disrupting the entire feminine care industry with their convenient subscription model, low cost delivery, and social giveback. In only a few short years, Arion has become a nationally & internationally recognized entity for her work in increasing feminine care access, health education, and advocacy through segments on NPR, Money Magazine, Buzzfeed, and more! Arion believes that the future is not only female, it’s Femly!

Matthias Alder joined Autolus as Chief Business Officer in July 2017. Previously, he served as EVP, BD&L and General Counsel of Sucampo Pharmaceuticals Inc. During his tenure at Sucampo, Matthias established a late stage development pipeline in orphan and rare diseases through acquisitions and strategic collaborations. Earlier in his career, he served as EVP Corporate Development and Legal Affairs at Cytos Biotechnology AG, and as SVP Administration and General Counsel of Micromet, Inc. Prior to Micromet, he was a partner in the Life Sciences Transactions Practice at Cooley LLP.

Engineer turned entrepreneur on a mission to solve the complex, level the playing field, and invest in the future.